Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.74B P/E - EPS this Y 8.50% Ern Qtrly Grth -
Income -325.1M Forward P/E -6.71 EPS next Y 25.70% 50D Avg Chg -
Sales 5.45M PEG - EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 3.84 EPS next 5Y - 52W High Chg -30.00%
Recommedations 1.60 Quick Ratio 6.21 Shares Outstanding 74.06M 52W Low Chg 32.00%
Insider Own 2.69% ROA -31.62% Shares Float 68.01M Beta 0.83
Inst Own 107.54% ROE -54.90% Shares Shorted/Prior 10.66M/11.13M Price 27.80
Gross Margin 92.25% Profit Margin - Avg. Volume 632,016 Target Price 66.75
Oper. Margin -1,807.66% Earnings Date May 1 Volume 595,855 Change -6.87%
About SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc. News
03/04/24 SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
02/29/24 SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
02/27/24 SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
02/27/24 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
02/22/24 SpringWorks Therapeutics to Present at Upcoming Investor Conferences
02/07/24 SpringWorks Therapeutics Inc Insider Sells Company Shares
02/05/24 SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
01/31/24 SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/08/24 SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
12/21/23 SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/08/23 SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/05/23 SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
12/04/23 SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
11/29/23 SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
11/28/23 SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment
11/27/23 SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
11/16/23 SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
11/02/23 SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial Results
11/02/23 SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/01/23 SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
SWTX Chatroom

User Image Night_Owl_Biotech Posted - 2 days ago

The attachment notes the share price activity over the last 6 weeks of the 5 (relatively) recent commercial-stage oncology focused biopharmas with FDA approved cancer therapies anticipated to do at least $1B (or very close to $1B/year). All 5 are down 10-20% more or less consistent with the change in the XBI. It's our experience oncology focused biopharmas are more often acquired than non. Of course this does not mean it will be the case in the future. As always, our data could be wrong. This is not investment advice. $IMCR $SWTX $DAWN $DCPH $XBI

User Image Okadarlan Posted - 2 days ago

$SWTX not selling till its below 30.

User Image RonIsWrong Posted - 3 days ago

$ALPN $XBI $MRUS $SWTX $FUSN FUSN ☑️ ALPN ☑️ SNDX _?_ SWTX - bring it !! KRYS _?_

User Image Fronte Posted - 6 days ago

$SWTX still boring . But not selling . See you in may …. They have also other drug in pipeline and Europe approval submitted. Forget about Bo any soon . Cheers and good luck

User Image WSRX Posted - 6 days ago

$SWTX can’t wait to see them blow out sales expectations for Q1

User Image patten1962 Posted - 6 days ago

$SWTX @MaxDanger @rooksleanne Good morning, look at the spread this morning on the Nasdaq. Bid $27.45 Ask $56.10 Trust what you know. Earnings come soon. We will be back over $50. Institutions still at 103%

User Image patten1962 Posted - 1 week ago

$SWTX Coming back a little.

User Image geothug Posted - 1 week ago

$SWTX

User Image Bornjever Posted - 1 week ago

$SWTX so the big boys like Black Rock etc have over 3 billion invested in this so believe they expect some fat earnings and not at once but every quarter more and more and by the way almost 42,000 buyers and less than 2,000 sellers with earnings coming beginning of May

User Image Fronte Posted - 1 week ago

$SWTX so they knew cpi and let it go. When we will see decent volumes it would mean bottom is in . Maybe it was today already. Good luck

User Image Bornjever Posted - 1 week ago

$SWTX agreed this is a cure for one type of cancer and seems like so many are getting beaten up but our earnings coming up on May 1 should give us a taste of what we can expect

User Image patten1962 Posted - 1 week ago

$SWTX Don't look at pre market here. All bs. Not even one share is sold.

User Image patten1962 Posted - 1 week ago

$SWTX Just checked the Nasdaq site. Short shares 10.5m Institutions still 103% Earnings still may 1st.

User Image Fronte Posted - 1 week ago

$SWTX bad cpi = lot of Vaseline needed. Finger crossed

User Image Bornjever Posted - 1 week ago

$SWTX this company has earnings coming that will show the sales of a drug that can completely cure those who normally would have died from soft cell cancer and this is a fairly rare disease but if you have it this is a cure and our sales and profits are going to be much better than ever and the next quarter is going to be better on May 1 we will get good news

User Image Fronte Posted - 1 week ago

$SWTX now is becoming very boring . Bad cpi and we see a 3 at the beginning

User Image patten1962 Posted - 1 week ago

$SWTX If any of you investors are on Twitter, please look for #. Spring works therapeutics. I will usually post something there. But I don't have enough followers. The more we get the word out on this stock, more buyers will get, and that'll put more pressure on the shorts.

User Image patten1962 Posted - 1 week ago

$SWTX I have not seen pre market action in a while

User Image tedevan Posted - 1 week ago

$SNDX $BPMC $IOVA $SWTX $IMCR

User Image patten1962 Posted - 1 week ago

$SWTX About 4 weeks to next earnings. I will hold till then. Short will do what they do. I will buy more! We all should buy a little everyday to make the shorts work!!!

User Image Night_Owl_Biotech Posted - 1 week ago

With Morgan Stanley in the news again about M&A & bio valuations with rate cuts, attached is a list of all of the commercial-stage oncology focused bios that have been acquired or merged/spun-off showing the # of months the LLE took place after its last FDA approval (sorted low to high). On the right side please find the remaining independent commercial-stage oncology focused biopharmas noting how long it has been since FDA approval. Be careful, our date info may not be perfect with those that have/had multiple FDA approvals. If commercial-stage oncology focused M&A is expected to be hot this year (versus clinical-stage) then it appears there are only so many with market caps of less than $10B & a recent approval (enough to drive significant growth to an acquirer). Obvious candidates would be $SWTX $IOVA $IMCR $SNDX & $BPMC

User Image Fronte Posted - 1 week ago

$SWTX these are all Bo buyers getting out . Hopefully they will be done soon

User Image NotOfTheBody Posted - 1 week ago

$SWTX Stock is a stone's throw away from entering oversold territory on the RSI 14. Already there on the RSI 9 at 27 and the Willams R% (14) at -94. Good time to add more if you can imo. Added another 500 at $43.75.

User Image patten1962 Posted - 1 week ago

$SWTX I am surprised by the drop from $50 but still not selling!

User Image Bornjever Posted - 1 week ago

$SWTX yes earning is real and will tell our story. Hard to guess what sales look like in first quarter but only medication highly rated for rare cancer. Very

User Image jeffrman777 Posted - 1 week ago

$SWTX A lot of June call OI

User Image Night_Owl_Biotech Posted - 1 week ago

It has been 7 weeks since the Betaville alert about a rumored $SWTX acquisition. The language in the Betaville alert suggested the process was so far along that one potential acquiror was outbid, meaning SWTX received at least a 1st non-binding offer before the date of the Betaville alert (again roughly 7 weeks ago). We reviewed the "Background of the Merger" included in 8 recent biopharma M&A transactions and noted certain dates on the attached document. As best we can tell, only IMGN took 7 weeks from the date they received their first offer. All 7 other transactions were done within 3 to 6 weeks of receiving the first offer. It is also very possible the Betaville alert was BS. SWTX remains a very attractive asset & takeout candidate with 2 probable Blockbusters with 18 years until patent expiration. Be careful, do not rely on the dates on the attachment. We may have made an inadvertent mistake so confirm the dates for yourself before taking any action. Good luck.

User Image patten1962 Posted - 1 week ago

$SWTX I will bet next short intrest report will be about 12m+ institutions are still holding.

User Image Stylerad Posted - 1 week ago

$SWTX watch it now

User Image Stylerad Posted - 1 week ago

$SWTX respond to 54

Analyst Ratings
HC Wainwright & Co. Buy Mar 6, 24
JP Morgan Overweight Mar 6, 24
Barclays Overweight Feb 29, 24
Wedbush Outperform Feb 26, 24
Barclays Overweight Jan 25, 24
Goldman Sachs Buy Nov 29, 23
HC Wainwright & Co. Buy Nov 29, 23
HC Wainwright & Co. Buy Nov 28, 23
HC Wainwright & Co. Buy Nov 20, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ashar Bhavesh Chief Commercial Off.. Chief Commercial Officer Feb 02 Sell 45.95 8,056 370,173 58,154 02/05/24
Pichl Daniel Chief People Officer Chief People Officer Feb 02 Sell 45.13 26,181 1,181,549 45,212 02/05/24
Pichl Daniel Chief People Officer Chief People Officer Feb 02 Option 27.64 16,250 449,150 71,393 02/05/24
Schwartz Jeffrey Lawrence Director Director Mar 16 Sell 28.50 1,750,000 49,875,000 3,081,307 03/20/23
Islam Saqib Chief Executive Offi.. Chief Executive Officer Oct 18 Sell 58.7 52,417 3,076,878 769,135 10/19/21
Smith L. Mary Chief Development Of.. Chief Development Officer Oct 13 Option 2.3 10,000 23,000 177,511 10/13/21
Smith L. Mary Chief Development Of.. Chief Development Officer Oct 13 Sell 55.97 10,000 559,700 167,511 10/13/21